Curcumin, a natural diarylheptanoid, is extensively used as a food additive or dietary supplement on the regular basis. It is known to have potential to encumber the drug transporters and hepatic drug metabolizing enzymes that lead to pharmacokinetic interactions with drug or food. Daclatasvir is a new orally acting drug for the treatment of chronic Hepatitis C Virus infections. This is a substrate of P-glycoprotein and CYP3A4 that are involved in the major pharmacokinetic interaction. Hence, the studies' aim is to assess for any possible pharmacokinetic interactions. Pharmacokinetic studies of daclatasvir in presence or absence of curcumin were carried out in Wistar rats following oral administration. Parallelly, the oral pharmacokinetics of daclatasvir was also determined in the presence of ketoconazole or quinidine. Studies revealed that plasma level of daclatasvir was not altered significantly during concomitant single dose administration of curcumin, whereas significantly decreased upon pretreatment for 7 days with curcumin at high dose level. Ketoconazole and quinidine markedly increase daclatasvir exposure following concomitant administration with daclatasvir. It can be concluded that dose adjustment is unlikely to be required for intermittent use of curcumin at low dose but cautious for chronic and concomitant use of curcumin at a high dose.
prescription and non-prescription allopathic drugs (Bahramsoltani, Rahimi, & Farzaei, 2017) . In another way, most of the people in the world have been taking herbs or herbal product casually without consulting with their healthcare providers for coadministration of herbal product with conventional therapy (Ekor, 2013; Zhang, Xue, & Fong, 2011) . This is a vital apprehension due to increase probability of a drug-drug or food-drug interaction. These make it imperative to investigate whether concomitant administration of curcumin with daclatasvir has any effect on daclatasvir plasma levels. This, above pharmacokinetic interaction study, might have serious consequences in the treatment of patients suffering from Hepatitis C Virus either by increasing its plasma level that will be helpful for dose reduction of daclatasvir or brutal decrease in plasma level leading to treatment failure that will be rather undesirable. Moreover, no interaction can also be valuable in terms of safety during coadministration (Manolakopoulos et al., 2016; Tarirai, Viljoen, & Hamman, 2010) .
There is no report on pharmacokinetic interaction of such a vital drug such as daclatasvir with curcumin in rat model as well as in clinical model. Hence, the objective of our present study is to explore the effect of curcumin as single dose as well as upon pretreatment with higher dose for certain days on oral pharmacokinetics of daclatasvir in Wistar rats. In parallel, daclatasvir being a substrate of P-gp and metabolizes through CYP3A4, the extent of the effect on daclatasvir pharmacokinetics by a known P-gp inhibitor (quinidine) and a known CYP3A4 inhibitor (ketoconazole) are also part of the present investigations.
| MATERIALS AND METHODS

| Materials
Curcumin (purity ≥99.0%) was purchased from Loba Chemie (Mumbai, India). Ketoconazole (purity ≥98%), quinidine (purity 97%), ammonium formate, and acetonitrile were purchased from Sigma Aldrich (St.
Louis, USA). Other chemicals or reagents used were of research grade.
Ultrapure water having the resistivity of 18.2 MΩ·cm was used for experimentations (Millipore water purification system, Bedford, USA). 
| Ethical prerequisite
| Animal's handling and care
Animal experimentation was carried out using healthy adult male Wistar rats that were housed in polypropylene cages at standard laboratory conditions such as temperature of 25 ± 2°C, relative humidity of 50 ± 20%, light cycle of 12 hr/12 hr, fed with pellet diet, and water ad libitum. Animals were acclimatized in these conditions for a minimum of 1 week before experimentation.
| Dose selection and preparation
Dose of daclatasvir dihydrochloride (7 mg/kg) was selected for rats by converting its human daily dose of 66 mg (equivalent to 60 mg daclatasvir), whereas dose of curcumin (2.5 or 5 or 10 mg/kg) was on the basis of bioenhancer mechanism that is effective at lower dose level (Atal & Bedi, 2010; Bhusari et al., 2007; Sachin et al., 2010; Shukla et al., 2016) . Ketoconazole (40 mg/kg) and quinidine (50 mg/ kg) dose for rats were selected on the basis of the maximum human single dose of 400 mg/day and 600 mg (quinidine sulphate) for every 4-6 hr (www.drugs.com). Individual dose formulation was prepared using 5% (v/v) dimethyl sulphoxide, 20% (v/v) solutol and 70% (v/v) water for oral administration of curcumin and daclatasvir dihydrochloride.
| Study design
Pharmacokinetic studies were performed following oral administration of daclatasvir dihydrochloride (7 mg/kg) as alone and in combination with curcumin or ketoconazole or quinidine. Different study groups are represented in Table 1 . Each study was done by using 15 animals, divided into three subgroups (n = 5) for sparse sampling Sharma et al., 2017) , that is, three blood samples (120 μl each) from every subgroups at different time points were collected from retro-orbital plexus. Animals were fasted for 10 hr prior to experimentation with free access to water. The single dose of curcumin or ketoconazole or quinidine (Groups 2, 3, 4, 6, and 7) was administered 0.5 hr before daclatasvir dosing. In case of Group 5, curcumin was administered for 7 days at 100 mg/kg, and on the 8th day, daclatasvir dihydrochloride was administered after 0.5 hr of curcumin administration at same dose level. Blood samples were collected in the microcentrifuge tube containing anticoagulant at 0.5, 1, 2, 4, 6, 8, 10, 12, and 16 hr after oral administration of daclatasvir dihydrochloride. Plasma was separated using centrifugation at 5,000 rpm for 10 min and stored at −80°C until analysis.
| Sample preparation
The stock solution of daclatasvir and sofosbuvir (internal standard, IS) was prepared in methanol and diluted further with acetonitrile to Daclatasvir hydrochloride (7 mg/kg) + ketoconazole (40 mg/ kg) concomitantly prepare standard solutions. An appropriate amount of these solutions were spiked into blank plasma for preparation of calibration standards and quality control samples. All solutions were stored in −20°C
freezer for further use. Plasma protein precipitation procedure was employed to recover daclatasvir from rat plasma. Nine point plasma calibration curve was prepared by using serially diluted standard solutions in the concentration of 3. 9, 7.8, 15.6, 31.25, 62.5, 125, 250, 500, and 1,000 ng/ml. Quality control samples at low (25 ng/ml), medium (400 ng/ml), and high (800 ng/ml) level were prepared by spiking standard solutions of daclatasvir into the blank plasma. Pharmacokinetic study samples (50 μl of plasma) were processed by adding 10 μl of IS. Then, sample was vortex mixed for 2 min and 190 μl of acetonitrile was added followed by centrifugation at 14,000 rpm for 10 min.
Supernatant layer was separated and injected into the liquid chromatography tandem mass spectrometry (LC-MS/MS) system.
| Bioanalysis
LC-MS/MS system (Make: Shimadzu; Model: 8030) was used for quantitation of daclatasvir in the processed samples from rat plasma with the modifications of previously reported method of analysis for daclatasvir in human plasma (Rezk, Bendas, Basalious, & Karim, 2016) . Chromatographic separation was achieved in Hiber HR RP-18
(50 × 2.1 mm, 3 μm) column using isocratic mobile phase composition of 10 mM ammonium formate (pH 3.5) and acetonitrile (50:50, %v/v).
Flow rate was kept at 0.3 ml/min. Autosampler was set at 4°C and column oven was maintained at ambient temperature. Quantitation was accomplished in positive ion mode for daclatasvir and IS using triple quad mass spectrometer equipped with electro spray ionization source. Detection of ion was performed in the multiple reaction monitoring (MRM) mode. Quadrupoles (Q1 and Q3) were set at unit resolution. Common mass spectrometry parameters and MRM transition pair for daclatasvir and IS are summarized in This developed method can provide high throughput analysis as total run time for analysis was less than 2.5 min. Calibration curve was linear over the concentration range of 3.9 to 1,000 ng/ml with a correlation coefficient greater than 0.99. The method was highly sensitive as it was very effective to measure concentration as low as 3.9 ng/ml in plasma. Intraday and Interday accuracy (95.66% to 107.03% and 95.76% to 103.20%) and precision (3.53 to 5.08 and 3.48 to 7.23) at different quality control level were well within the acceptance limits.
Single step protein precipitation method was very effective as more than 80% daclatasvir was recovered from plasma in reproducible, precise, and consistent manner. This is the first time report for determination of daclatasvir in rat plasma.
Pharmacokinetic studies of daclatasvir dihydrochloride ( Heat block temperature (°C) 300
Nebulizing gas flow (L/min) 3 363.1 ± 15.0 ng/ml and 3,147.7 ± 124.8 ng·hr/ml, respectively. After ketoconazole, a known CYP3A4 inhibitor (Group 6) at 40 mg/kg coadministration with daclatasvir, AUC 0-t , as well as AUC 0-∞ were significantly enhanced to 10,780.6 ± 757.0 and 11,998.2 ± 1056.1 ng·hr/ml, respectively. C max was also elevated to 1,136.2 ± 79.2 ng/ml that have statistical significance as compared 
| DISCUSSION
This is a well known fact that coadministration could achieve improvement in plasma concentration of P-gp and CYP substrates with P-gp and CYP inhibitors (Endres, Hsiao, Chung, & Unadkat, 2006; Ondieki et al., 2017) . Daclatasvir is a substrate and inhibitor of P-gp; weak inhibitor but not a substrate for organic anion transporting polypeptide (OATP) and breast cancer resistance protein (Garimella et al., 2015) . As daclatasvir is metabolized primarily through CYP3A4, it is advised that daclatasvir should not be given in combination with strong inducers or inhibitors of the CYP3A4 hepatic isoenzymes (United States Food and Drug administration (USFDA), 2016). We investigated the consequences of coadministration of daclatasvir and curcumin because curcumin is an inhibitor of P-gp, OATP 1B1 and 1B3, and breast cancer resistance protein (Bahramsoltani et al., 2017) . Worldwide consumption of curcumin as a spice or food additive or dietary supplement made these investigations imperative.
Curcumin upon coadministration with a single dose of daclatasvir elevated the plasma concentration of daclatasvir by maximum 2-3% that can be considered negligible. In the era of bioenhancer, the attempt has been taken intentionally by using coadministration for a positive pharmacokinetic interaction of drug to improve the plasma drug concentration and thereby oral bioavailability (Randhawa, Kullar, & Rajkumar, 2011; Tatiraju, Bagade, Karambelkar, Jadhav, & Kadam, 2013) . Rifampicin is the classical example as rifampicin in combination with piperine as bioenhancer has successfully lowered the dose of rifampicin from 450 to 200 mg per tablet and already been marketed in India (Atal & Bedi, 2010) . Curcumin is also found to enhance the bioavailability of the number of drugs such as celiprolol, midazolam, and paclitaxel (Bahramsoltani et al., 2017; Kesarwani & Gupta, 2013) . These improvements in oral exposure of drugs are ultimately beneficial for poor bioavailable drugs or drugs having dose-dependent side effects for dose reduction (Bhusari et al., 2007; Najar et al., 2011) . cantly. On the contrary, quinidine also enhanced the AUC 0-∞ by more than 90%, which was statistically significant, but C max and AUC 0-t were not altered up to the significant extent. Quinidine is a strong inhibitor of P-gp but it is also a substrate and an inducer of P-gp (Srivalli & Lakshmi, 2012) . This may be the reason to the resultant effect of quinidine on daclatasvir oral pharmacokinetics. Clearance of daclatasvir was also decreased significantly. T max and mean residence time of daclatasvir were also raised upon coadministration of curcumin. Curcumin might have poor efficacy to up regulate absorption and/or down regulate the metabolism of daclatasvir and for which plasma concentrations were declined. This can be depicted from the above results and its related discussion. It is reported in the literature that curcumin can inhibit P-gp in dose-dependent manner at micromolar concentration range and inhibit CYP3A4 competitively with low potency (>10 μM; Bahramsoltani et al., 2017) . Possibly, this can be due to large portion of curcumin entering the intestinal epithelium is extensively metabolized intracellularly, and therefore P-gp binding is reduced (Juan et al., 2007) . On the other hand, it was also reported that Curcuma longa extract (100 μM) also increased the activity of Pgp in Caco-2 cells (Bahramsoltani et al., 2017) . Moreover, quite a few investigations appear to indicate unexpectedly the opposite results related to complex ABC transporter systems (Cascorbi, 2006; Gutmann, Fricker, & Drewe, 1999) . The overall effect of curcumin may be correlated to might be compensated by overexpression of other transporters having an affinity for daclatasvir.
| CONCLUSION
Likelihood of pharmacokinetic interaction is enhanced when natural products such as curcumin are used concomitantly with conventional drugs. Hence, the effect of curcumin on oral pharmacokinetics of daclatasvir is prudent to exercise for any possible drug-drug and/or food-drug interaction. Pharmacokinetic studies of daclatasvir were carried out after oral administration in rat as alone and in combination with curcumin (single dose or pretreatment at high dose) or quinidine (single dose), a known P-gp inhibitor or ketoconazole (single dose), a known CYP3A4 inhibitor. This is reported for first time in the literature including the method of rat plasma sample analysis. Based on the results, the net effect of curcumin coadministration could not be able to raise plasma concentration of daclatasvir rather plasma concentration was reduced significantly upon pretreatment at a high dose level. Results of ketoconazole and quinidine individual coadministration with daclatasvir depicted that a strong CYP3A4 inhibitor could augment absorption and delay metabolism of daclatasvir more effectively to enhance plasma concentration of daclatasvir. Based on the reported potency of curcumin to inhibit P-gp and CYP3A4, the overall effect obtained at high dose level may be due to the activation of the other transporter systems for which further studies have to be performed. Finally, daclatasvir dose adjustment is unlikely to be required for intermittent and single dose, but should be taken cautiously in the long-term at high dose level, which may lead to treatment failure.
Nevertheless clinical significance needs to be ascertained.
